Does a Single Low Dose Preoperative Intravenous Erythropoietin Affect Postoperative Blood Loss and Transfusion in Elderly Hip Fracture Patients Receiving Intravenous Iron Therapy: A Randomized Controlled Trial

• Main Authors: Chavarat Jarungvittayakon, Paphon Sa-ngasoongsong, Kitchai Luksameearunothai, Norachart Sirisreetreerux, Noratep Kulachote, Thumanoon Ruangchaijatuporn, Sasivimol Rattanasiri, Suporn Chuncharunee, Patarawan Woratanarat, Pongsthorn Chanplakorn, ชวรัฐ จรุงวิทยากร, ปพน สง่าสูงส่ง, กิจชัย ลักษมีอรุโณทัย, นรชาติ ศิริศรีตรีรักษ์, นรเทพ กุลโชติ, ธรรมนูญ เรืองชัยจตุพร, ศศิวิมล รัตนสิริ, สุภร จันท์จารุณี, ภัทรวัณย์ วรธนารัตน์, พงศธร ฉันท์พลากร
• Other Authors: Mahidol University. Faculty of Medicine Ramathibodi Hospital. Department of Orthopedics
• Format: Original Article
• Language: English
• Published: 2022
• Subjects: Recombinant human erythropoietin; Elderly hip fracture; Allogeneic blood transfusion; Postoperative; Blood Loss; ฮอร์โมนกระตุ้นการสร้างเม็ดเลือดสังเคราะห์; ภาวะกระดูกสะโพกหักในผู้สูงอายุ; อัตราการได้รับเลือดหลังผ่าตัด; การสูญเสียเลือดหลังผ่าตัด
• Online Access: https://repository.li.mahidol.ac.th/handle/123456789/72248
• Institution: Mahidol University

Background: Combined recombinant human erythropoietin (rHuEPO) and iron therapy significantly reduced postoperative blood loss (PBL) and allogeneic blood transfusion (ABT) in elderly hip fracture (HF) patients. However, the minimum effective rHuEPO dosage and route had not been studied before. Objective: To evaluate the efficacy of single low dose preoperative intravenous rHuEPO on PBL and ABT in elderly HF. Methods: A randomized controlled trial (RCT) in 32 elderly HF underwent surgical intervention was conducted. The patients were randomly assigned to receive a single dose of 10 000 IU rHuEPO (EPO group, n = 16) or placebo (control group, n = 16) on admission. All patients were given 200-mg iron sucrose intravenously for 3 days after admission. Perioperative data, outcome related to PBL, ABT, rHuEPO adverse effects, and functional outcome during 1-year period were collected and analyzed. Results: There was no significant difference in demographic data, postoperative complication, and functional outcome between both groups (P < .05). Total hemoglobin loss (THL) and the number of patients receiving ABT in EPO group (2.1 ± 1.0 g/dL and 12 patients) did not significant differ from those in control group (2.2 ± 0.8 g/dL and 10 patients) (P = .81 and P = .44, respectively). However, EPO group demonstrated a nonsignificant greater in hemoglobin recovery (P = .07) and increase in reticulocyte count (P = .10). Conclusion: Combined single low dose preoperative intravenous rHuEPO with iron therapy does not significantly reduce PBL and ABT in elderly HF compared to who received intravenous iron therapy alone. However, this adjunct rHuEPO may hasten the hemoglobin recovery and helpful for the patients’ outcome.